{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-087289","form_type":"8-K","ticker":"ABVC","cik":"0001173313","company_name":"ABVC BIOPHARMA, INC.","filed_at":"2023-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.413400+00:00","generated_at":"2026-06-08T02:01:39.550384+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ABVC BioPharma Q3 2023 revenue down 62% to $16K; net loss improves 11% to $3.37M","bullets":["Q3 2023 revenue $15,884 vs $42,269 in Q3 2022; cash increased to $500K from $85K at year-end 2022.","Net loss narrowed to $3.37M from $3.78M; operating expenses fell 43% to $2.14M.","MDD drug ABV-1504 completes Phase II; licensing deal with Xinnovation worth up to $20M for China rights.","Signed global licensing agreement with AIBL for CNS drugs valued at $667M; ABVC and BioLite to receive 23M AIBL shares at $10/share plus milestones.","Regained Nasdaq minimum bid price compliance; shareholders' equity at $9.1M."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-087289","json":"https://secwatch.observer/filing/0001213900-23-087289.json","markdown":"https://secwatch.observer/filing/0001213900-23-087289.md","text":"https://secwatch.observer/filing/0001213900-23-087289.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023087289/0001213900-23-087289-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023087289/ea188352-8k_abvcbio.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T02:01:39.550384+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"34e79008050415470c2c3ebed4eee92f9f5d3210","claim":"ABVC BIOPHARMA, INC. reported third quarter ended September 30, 2023 results: revenue $15,884, net income The net loss was $3,368,080.","evidence_excerpt":"achieved a total shareholders’ equity of $9.10M and therefore believes it has regained the compliance with NASDAQ’s shareholders’ equity requirement. ● Revenues . We generated $15,884 and $42,269 in revenues for the three months ended September 30, 2023 and 2022, respectively. The decrease in revenues was due to completion of ongoing projects and awaiting new","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173313/000121390023087289/0001213900-23-087289-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$15,884"},{"label":"Net income","value":"The net loss was $3,368,080"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}